Tildrakizumab

Introduction: What is Tildrakizumab?

Tildrakizumab is a biologic medication primarily used to treat moderate to severe plaque psoriasis in adults. It is a monoclonal antibody that specifically targets interleukin-23 (IL-23), a cytokine involved in inflammatory processes. By inhibiting IL-23, Tildrakizumab helps reduce the inflammation and skin cell overproduction associated with psoriasis, leading to clearer skin and improved quality of life for patients.

Uses of Tildrakizumab

Tildrakizumab is approved for the treatment of:

• Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

It may also be used in clinical settings for other inflammatory conditions, although its primary indication remains in psoriasis.

How Does It Work?

Tildrakizumab works by blocking the action of interleukin-23, a protein that plays a crucial role in the inflammatory response of the immune system. In psoriasis, the immune system mistakenly attacks healthy skin cells, leading to rapid skin cell turnover and the formation of plaques. By inhibiting IL-23, Tildrakizumab helps to restore the balance in the immune system, reduce inflammation, and slow down the excessive growth of skin cells.

Dosage and Administration

Tildrakizumab is administered via subcutaneous injection. The standard dosage for adults is:

• Initial Dose: 100 mg in week 0 and week 4.
• Maintenance Dose: 100 mg every 12 weeks thereafter.

For pediatric patients, the safety and efficacy of Tildrakizumab have not been established, and it is not recommended for use in individuals under 18 years of age.

Side Effects of Tildrakizumab

Common side effects may include:

• Injection site reactions (redness, swelling, itching)
• Upper respiratory infections
• Headache
• Fatigue

Serious side effects can include:

• Serious infections
• Hypersensitivity reactions (rash, itching, swelling)

Patients should report any unusual symptoms to their healthcare provider promptly.

Drug Interactions

Tildrakizumab may interact with other medications, particularly those that affect the immune system. Major drug interactions include:

• Live vaccines: Patients should avoid live vaccines while on Tildrakizumab due to the risk of infections.
• Immunosuppressants: Caution is advised when used with other immunosuppressive therapies, as this may increase the risk of infections.

Always inform your healthcare provider about all the medications and supplements you are taking.

Benefits of Tildrakizumab

The clinical advantages of Tildrakizumab include:

• Targeted therapy: Specifically targets IL-23, leading to effective management of psoriasis.
• Long-lasting effects: With maintenance dosing every 12 weeks, it offers convenience for patients.
• Improved quality of life: Many patients experience significant skin clearance and symptom relief, enhancing their overall wellbeing.

Contraindications of Tildrakizumab

Tildrakizumab should be avoided in the following situations:

• Patients with a known hypersensitivity to Tildrakizumab or any of its components.
• Individuals with active infections, as the medication can suppress the immune system.
• Pregnant or breastfeeding women: There are no adequate data; use only if potential benefit justifies risk?consult provider.

Precautions and Warnings

Before starting Tildrakizumab, patients should undergo the following:

• Screening for tuberculosis (TB) and other infections.
• Liver function tests to monitor potential liver issues.
• Regular follow-ups to assess the effectiveness and any side effects of the treatment.

FAQs

• What is Tildrakizumab used for? Tildrakizumab is primarily used to treat moderate to severe plaque psoriasis in adults.
• How is Tildrakizumab administered? It is given as a subcutaneous injection, typically starting with two doses followed by maintenance doses every 12 weeks.
• What are the common side effects? Common side effects include injection site reactions, upper respiratory infections, headache, and fatigue.
• Can Tildrakizumab be used for children? No, Tildrakizumab is not recommended for individuals under 18 years of age.
• What should I do if I miss a dose? Administer as soon as possible if <3 days late; contact provider if >3 days.
• Are there any serious side effects? Yes, serious side effects can include allergic reactions, infections, and liver problems.
• Can I receive vaccines while on Tildrakizumab? Live vaccines should be avoided while on Tildrakizumab due to the risk of infections.
• How long does it take to see results? Improvements often seen by week 4-12; PASI 75 in ~60% by week 12 per trial.
• Is Tildrakizumab safe during pregnancy? Pregnant women should consult their healthcare provider before using Tildrakizumab.
• What should I do if I experience side effects? Report any side effects to your healthcare provider immediately for further evaluation.

Brand Names

Tildrakizumab is marketed under the brand name Ilumya.

Conclusion

Tildrakizumab represents a significant advancement in the treatment of moderate to severe plaque psoriasis. By specifically targeting IL-23, it offers a targeted approach to managing this chronic condition, improving patients' skin health and overall quality of life. As with any medication, it is essential to discuss its use with a healthcare provider to ensure it is appropriate for your individual health needs.